Asset profile
Masupirdine
Small molecule
Evidence outlook · lead readout
NCT02580305 · Alzheimer's Disease
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02580305: This was a large, randomized, blinded, placebo-controlled trial using a well-established cognitive scale as its main measure, which is a strong design. But neither the low-dose group (p=0.41) nor the high-dose group (p=0.90) showed a statistically meaningful difference from placebo on that measure, so the trial does not show masupirdine improved cognition beyond placebo at either dose.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.